197 related articles for article (PubMed ID: 24023314)
1. Vascular endothelial growth inhibitor (VEGI) is an independent indicator for invasion in human pituitary adenomas.
Jia W; Sander AJ; Jia G; Ni M; Liu X; Lu R; Jiang WG
Anticancer Res; 2013 Sep; 33(9):3815-22. PubMed ID: 24023314
[TBL] [Abstract][Full Text] [Related]
2. Expression of the mTOR pathway regulators in human pituitary adenomas indicates the clinical course.
Jia W; Sanders AJ; Jia G; Liu X; Lu R; Jiang WG
Anticancer Res; 2013 Aug; 33(8):3123-31. PubMed ID: 23898069
[TBL] [Abstract][Full Text] [Related]
3. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
[TBL] [Abstract][Full Text] [Related]
4. Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas.
Iuchi T; Saeki N; Osato K; Yamaura A
Acta Neurochir (Wien); 2000; 142(12):1345-51. PubMed ID: 11214627
[TBL] [Abstract][Full Text] [Related]
5. The differential expression of vascular endothelial growth inhibitor isoforms, VEGI251, VEGI174 and VEGI192 in human clear-cell renal cell carcinoma.
Zhang N; Wu P; Wu L; Shayiremu D; Shan H; Ye L; Jiang WG; Gong K; Yang Y
Cancer Genomics Proteomics; 2013; 10(1):47-53. PubMed ID: 23382586
[TBL] [Abstract][Full Text] [Related]
6. The expression of vascular endothelial growth factor and its receptors (flt1/fms, flk1/KDR, flt4) and vascular endothelial growth inhibitor in the bovine uterus during the sexual cycle and their correlation with serum sex steroids.
Sağsöz H; Saruhan BG
Theriogenology; 2011 Jun; 75(9):1720-34. PubMed ID: 21396695
[TBL] [Abstract][Full Text] [Related]
7. Expression and function of vascular endothelial growth inhibitor in aged porcine bladder detrusor muscle cells.
Wang M; Zhang N; Wang W; Wang B; Xu Z; Yang Y
Biogerontology; 2013 Oct; 14(5):543-56. PubMed ID: 24030243
[TBL] [Abstract][Full Text] [Related]
8. Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours.
Onofri C; Theodoropoulou M; Losa M; Uhl E; Lange M; Arzt E; Stalla GK; Renner U
J Endocrinol; 2006 Oct; 191(1):249-61. PubMed ID: 17065408
[TBL] [Abstract][Full Text] [Related]
9. Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour invasiveness but not with G-protein alpha subunit (gsp) mutation in human GH-secreting pituitary adenomas.
Morita K; Takano K; Yasufuku-Takano J; Yamada S; Teramoto A; Takei M; Osamura RY; Sano T; Fujita T
Clin Endocrinol (Oxf); 2008 Mar; 68(3):435-41. PubMed ID: 18070145
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells.
Kumanishi S; Yamanegi K; Nishiura H; Fujihara Y; Kobayashi K; Nakasho K; Futani H; Yoshiya S
Int J Oncol; 2019 Jul; 55(1):167-178. PubMed ID: 31180533
[TBL] [Abstract][Full Text] [Related]
11. Sodium valproate, a histone deacetylase inhibitor, modulates the vascular endothelial growth inhibitor-mediated cell death in human osteosarcoma and vascular endothelial cells.
Yamanegi K; Kawabe M; Futani H; Nishiura H; Yamada N; Kato-Kogoe N; Kishimoto H; Yoshiya S; Nakasho K
Int J Oncol; 2015 May; 46(5):1994-2002. PubMed ID: 25778932
[TBL] [Abstract][Full Text] [Related]
12. Thyrotrophin (TSH)-secreting pituitary macroadenoma with cavernous sinus invasion.
Kon YC; Loh KC; Tambyah JA; Lim LH; Marshall JC
Singapore Med J; 2001 Sep; 42(9):433-7. PubMed ID: 11811613
[TBL] [Abstract][Full Text] [Related]
13. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up.
Trouillas J; Roy P; Sturm N; Dantony E; Cortet-Rudelli C; Viennet G; Bonneville JF; Assaker R; Auger C; Brue T; Cornelius A; Dufour H; Jouanneau E; François P; Galland F; Mougel F; Chapuis F; Villeneuve L; Maurage CA; Figarella-Branger D; Raverot G; ; Barlier A; Bernier M; Bonnet F; Borson-Chazot F; Brassier G; Caulet-Maugendre S; Chabre O; Chanson P; Cottier JF; Delemer B; Delgrange E; Di Tommaso L; Eimer S; Gaillard S; Jan M; Girard JJ; Lapras V; Loiseau H; Passagia JG; Patey M; Penfornis A; Poirier JY; Perrin G; Tabarin A
Acta Neuropathol; 2013 Jul; 126(1):123-35. PubMed ID: 23400299
[TBL] [Abstract][Full Text] [Related]
14. The role of vascular endothelial growth factor and vascular endothelial growth inhibitor in clinical outcome of traumatic brain injury.
Li M; Jia Q; Chen T; Zhao Z; Chen J; Zhang J
Clin Neurol Neurosurg; 2016 May; 144():7-13. PubMed ID: 26945876
[TBL] [Abstract][Full Text] [Related]
15. Expression of vascular endothelial growth inhibitor (VEGI) in human urothelial cancer of the bladder and its effects on the adhesion and migration of bladder cancer cells in vitro.
Zhang N; Sanders AJ; Ye L; Kynaston HG; Jiang WG
Anticancer Res; 2010 Jan; 30(1):87-95. PubMed ID: 20150621
[TBL] [Abstract][Full Text] [Related]
16. Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients.
Parr C; Gan CH; Watkins G; Jiang WG
Angiogenesis; 2006; 9(2):73-81. PubMed ID: 16758268
[TBL] [Abstract][Full Text] [Related]
17. Correlation of VEGF production with IL1 alpha and IL6 secretion by human pituitary adenoma cells.
Borg SA; Kerry KE; Royds JA; Battersby RD; Jones TH
Eur J Endocrinol; 2005 Feb; 152(2):293-300. PubMed ID: 15745939
[TBL] [Abstract][Full Text] [Related]
18. Suppression of renal cell carcinoma growth in vivo by forced expression of vascular endothelial growth inhibitor.
Zhang N; Wu P; Shayiremu D; Wu L; Shan H; Ye L; Zhao X; Cai J; Jiang WG; Gong K; Yang Y
Int J Oncol; 2013 May; 42(5):1664-73. PubMed ID: 23545578
[TBL] [Abstract][Full Text] [Related]
19. An ACTH and FSH producing invasive pituitary adenoma with Crooke's hyalinization.
Kamijo K; Sato M; Saito T; Yachi A; Minase T; Noro H; Kawahara T
Pathol Res Pract; 1991 Jun; 187(5):637-41. PubMed ID: 1717963
[TBL] [Abstract][Full Text] [Related]
20. Survivin products in pituitary tumors.
Jankowska A; Wasko R; Waligorska-Stachura J; Andrusiewicz M; Jaskula M; Liebert W; Sowinski J
Neuro Endocrinol Lett; 2008 Dec; 29(6):1033-7. PubMed ID: 19112393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
